Porton Pharma Solutions 博腾股份
25 significant filings since 29 May 2026: 14 on equity incentive, 8 on buyback and 1 on pledge released, and 2 other kinds. The latest, on 14 Sep 2026: 关于调整2026年限制性股票激励计划首次授予激励对象名单及权益数量的公告. On 14 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to fall by 876.05% to 1,023.87% from the same period a year earlier.
自 29 May 2026 起有 25 份重大公告：equity incentive 14 份、buyback 8 份、pledge released 1 份，另有 2 类。最新一份（14 Sep 2026）：关于调整2026年限制性股票激励计划首次授予激励对象名单及权益数量的公告。14 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期下降 876.05% 至 1,023.87%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 29 Nov 2021 | 民生证券 | 周超泽,叶小桃 | Outperform 增持 | ▲ | Buy 买入 |
| 13 Jul 2021 | 民生证券 | 王芳 | Buy 买入 | ▼ | Outperform 增持 |
| 21 Jan 2021 | 西南证券 | 杜向阳,马云涛 | Outperform 增持 | ▲ | Buy 买入 |
| 10 Jul 2020 | 民生证券 | 孙建 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 中邮证券 | 盛丽华,辛家齐 | Buy 买入 | 24 Apr 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。